Remote ischemic postconditioning (RIPC) is suggested to protect the cerebral cell against ischemia in various settings. However, the effect of RIPC in patients with acute ischemic stroke who undergo thrombolysis has yet to be examined. In this single-center, randomized controlled trial, we examined the effect of RIPC on the resolution of nerve function deficient in response to thrombolysis. Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis. The primary endpoint was the recovery of nerve function deficient assessed by National Institutes of Health Stroke Scale(NIHSS), Activities of Daily Living(ADL), Modified Rankin Scale(mRS), CT cerebral perfusion imaging (CTP) and CT angiography(CTA). Secondary endpoints included the following: angiogenesis assessed by the level of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF).
Full Title of Study: “The Recovery of Nerve Function Deficient of Combined Intravenous Thrombolysis and Remote Ischemic Post-conditioning in Acute Ischemic Stroke.”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Single (Participant)
- Study Primary Completion Date: December 31, 2020
- Device: RIPC device (IPC-906X)
- Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis.
Arms, Groups and Cohorts
- Experimental: RIPC
- Remote ischemic postconditioning（RIPC）：Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after thrombolysis while in-hospital.
- No Intervention: Blank control group(BC)
- Blank control group:Patients in the BC group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin, 100-300 mg/d) and lipid-lowering (atorvastatin, 20 mg/d) drugs,throughout the 14 days in-hospital period without remote ischemic postconditioning after thrombolysis.
Clinical Trial Outcome Measures
- the percentage of patients with a favorable outcome, defined as a score of 0 or 1 on the modified Rankin scale (mRS).
- Time Frame: Day 90
- the percentage of functional recovery at discharge and at day 90, as measured by the NIHSS, the Barthel index (BI) and the mRS
- Time Frame: Day 90 and at discharge(up to day 14)
- we measured how many patients achieved a score of 0 or 1 for the NIHSS, 95 for the BI, and 0 – 2 for the mRS.
- Plasma biomarker concentrations
- Time Frame: Day 1 and at discharge ( up to day 14)
- Venous blood was drawn before the administration of IV tPA and at the end of hospitalization to determine the effect of repeated RIPC on anti-inflammatory (S100-β), vascular (VEGF, bFGF), anti-edema (MMP9), anti-oxidants (OH1) and other pathways (BDNF, HSP).
Participating in This Clinical Trial
- In accordance with the Guideline of Thrombolysis in Acute Ischemic Stroke and accomplish intravenous thrombolytic therapy using alteplase;
- The consciousness of patients are conscious,somnolence,confusion and stupor，can comply better with the RIPC treatment;
- Acute ischemic stroke confirmed by cranial CT/MRI;
- Provision of written informed consent.
- History of cerebral embolism,cerebral hemorrhage, brain tumor, brain trauma or other brain lesion;
- Severe cardiac, liver, or kidney disease, malignancy, systemic organ dysfunction;
- Blood pressure <90/60 mmHg or >200/110 mmHg after treatment;
- Dementia or mental illness;
- History of major surgery or trauma 4 weeks prior to admission;
- Failure to provide informed consent.
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- First Affiliated Hospital Xi’an Jiaotong University
- Provider of Information About this Clinical Study
- Overall Official(s)
- Guogang Luo, MD, PHD, Principal Investigator, First Affiliated Hospital Xi’an Jiaotong University
- Overall Contact(s)
- Guogang Luo, doctor, 0086-13991974085, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.